ATAI News and Press, ATAI Life Sciences N.V. From 05/15/24

First participant dosed in Phase 1b trial of VLS-01 with data expected in 2H’24; Phase 2 study in TRD patients anticipated to initiate around YE’24 Beckley Psytech’s Phase 2a study of BPL-003 in TRD patients showed rapid and durable antidepressant effects; Phase 2b to...

AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...

American researchers will be able to study various psychedelics and their effects on the human body much more effectively if hallucinogens are finally deregulated after decades of state and federal prohibition. Similar to how cannabis research opened up after dozens of states legalized either r...

2024-05-07 05:54:17 ET More on psychedelic therapies MindMed: Breakthrough Status From FDA For LSD Therapy COMPASS Pathways: Will MDMA-Assisted Therapy Pave The Way? Mind Medicine: GAD Program Success Continues With BTD MindMed releases promising data on LSD-...

2024-04-29 13:37:07 ET More on psychedelic drug developers Psychedelic drugs market to break $7B in 2029 led by these 3 meds Cybin spikes after FDA breakthrough tag for psychedelic therapy Psychedelic stocks gain after FDA priority review for MDMA therapy ...

The BPL-003 Phase 2a trial is an open-label study investigating BPL-003 as both monotherapy and adjunctive to SSRIs in patients with Treatment Resistant Depression. Initial results from the recently completed monotherapy Part 1 of the study were shared in M...

New research has looked into the influence of psychedelic substances on sexual functioning and satisfaction. This comes as scientists learn more about the promising potential of psychedelics in treating mental-health conditions. Various studies have looked into the effectiveness of psilocybin ...

BPL-003 is Beckley Psytech’s novel patent-protected benzoate salt formulation of 5-MeO-DMT that is administered intranasally. BPL-003 was shown to be safe and well-tolerated with a predictable pharmacokinetic profile and a reliable induction of subjective psychedelic effects with s...

Legislators in the House of Representatives in the state of Missouri have awarded preliminary approval to a budget measure that would allocate $10 million from opioid settlement funds to study grants focused on researching psilocybin’s use in treating opioid-use disorder. The initiativ...

2024-04-03 10:47:15 ET More on ATAI Life Sciences De-Risking Psychedelics: Compass Pathways, Cybin And Atai Psychedelic stocks gain after FDA priority review for MDMA therapy Atai buys 35.5% stake in psychedelic drug developer, stock rallies 18% Seeking Alpha...